---
title: "Ascendis Pharma Reports Second Quarter 2026 Financial Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295794147.md"
description: "In the second quarter of 2026, product revenue reached €315 million, showing a significant increase of 105% year-over-year. Out of this total, €252 million came from YORVIPATH®, €55 million from SKYTROFA®, and €8 million from YUVIWEL®."
datetime: "2026-08-13T11:35:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295794147.md)
  - [en](https://longbridge.com/en/news/295794147.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295794147.md)
generator: "portal-rs"
---

# Ascendis Pharma Reports Second Quarter 2026 Financial Results

In the second quarter of 2026, product revenue reached €315 million, showing a significant increase of 105% year-over-year. Out of this total, €252 million came from YORVIPATH®, €55 million from SKYTROFA®, and €8 million from YUVIWEL®.

### Related Stocks

- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)

## Related News & Research

- [Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes](https://longbridge.com/en/news/297515082.md)
- [Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026 | ASND Stock News](https://longbridge.com/en/news/296951291.md)
- [This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday](https://longbridge.com/en/news/297205620.md)
- [Ascendis Pharma Files Strong Interim Q2 2026 Results on Form 6-K](https://longbridge.com/en/news/295797900.md)
- [Legal Overhang Lifted by BioMarin Settlement, Supporting Buy Rating on Ascendis as Investors Refocus on Yorvipath-Driven Growth](https://longbridge.com/en/news/297671489.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**